CanadaBis Capital Inc banner
C

CanadaBis Capital Inc
OTC:CNADF

Watchlist Manager
CanadaBis Capital Inc
OTC:CNADF
Watchlist
Price: 0.02 USD Market Closed
Market Cap: $2.8m

EV/OCF

-4.3
Current
7%
Cheaper
vs 3-y average of -4.6

Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.

EV/OCF
-4.3
=
Enterprise Value
$9.6m
/
Operating Cash Flow
CA$-2.1m

Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.

EV/OCF
-4.3
=
Enterprise Value
$9.6m
/
Operating Cash Flow
CA$-2.1m

Valuation Scenarios

CanadaBis Capital Inc is trading above its industry average

If EV/OCF returns to its Industry Average (10.4), the stock would be worth $-0.05 (343% downside from current price).

Statistics
Positive Scenarios
0/2
Maximum Downside
-380%
Maximum Upside
No Upside Scenarios
Average Downside
362%
Scenario EV/OCF Value Implied Price Upside/Downside
Current Multiple -4.3 $0.02
0%
Industry Average 10.4 $-0.05
-343%
Country Average 11.9 $-0.06
-380%

Forward EV/OCF
Today’s price vs future operating cash flow

Not enough data available to calculate forward EV/OCF

Peer Comparison

All Multiples
EV/OCF
P/E
All Countries
Close
Market Cap EV/OCF P/E
CA
CanadaBis Capital Inc
OTC:CNADF
2.1m USD -4.3 -1.6
US
Eli Lilly and Co
NYSE:LLY
835.2B USD 51.6 40.5
US
Johnson & Johnson
NYSE:JNJ
547.8B USD 23.4 26
CH
Roche Holding AG
SIX:ROG
248.4B CHF 15.2 20.1
UK
AstraZeneca PLC
LSE:AZN
216.4B GBP 21.1 28
CH
Novartis AG
SIX:NOVN
223.1B CHF 15.2 19.5
US
Merck & Co Inc
NYSE:MRK
276.9B USD 18.8 15.2
IE
Endo International PLC
LSE:0Y5F
244.4B USD 936 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 10.5 11.4
US
Pfizer Inc
NYSE:PFE
153.5B USD 17.2 19.8
US
Bristol-Myers Squibb Co
NYSE:BMY
118.2B USD 10.6 16.8
P/E Multiple
Earnings Growth PEG
CA
C
CanadaBis Capital Inc
OTC:CNADF
Average P/E: 21.9
Negative Multiple: -1.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
40.5
32%
1.3
US
Johnson & Johnson
NYSE:JNJ
26
8%
3.3
CH
Roche Holding AG
SIX:ROG
20.1
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
28
25%
1.1
CH
Novartis AG
SIX:NOVN
19.5
14%
1.4
US
Merck & Co Inc
NYSE:MRK
15.2
14%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
11.4
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.8
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.8
16%
1

Market Distribution

Lower than 100% of companies in Canada
Percentile
0th
Based on 1 926 companies
0th percentile
-3.7
Low
0 — 7.9
Typical Range
7.9 — 19.5
High
19.5 —
Distribution Statistics
Canada
Min 0
30th Percentile 7.9
Median 11.9
70th Percentile 19.5
Max 22 577.3

CanadaBis Capital Inc
Glance View

Market Cap
2.8m USD
Industry
Pharmaceuticals

CanadaBis Capital Inc. is a capital pool company, which engages in the identification and evaluation of assets or a business. The company is headquartered in Rocky Mountain House, Alberta. The company went IPO on 2017-03-08. The Company’s segments include Wholesale, Retail, and Extraction and Tolling. The Wholesale segment cultivates and distributes cannabis and cannabis products to and through, provincial liquor and cannabis boards that are subsequently sold to end consumers. The Retail segment involves in the sale of cannabis and cannabis-related products to end consumers on premise owned and operated by the Company. The Extraction and Tolling segment provides cannabinoid extraction services to other licensed producers. The Company’s subsidiaries include Stigma Pharmaceuticals Inc., 1998643 Alberta Ltd, Full Spectrum Labs Ltd, 2103157 Alberta Ltd. and Goldstream Cannabis Inc.

CNADF Intrinsic Value
0.09 USD
Undervaluation 78%
Intrinsic Value
Price $0.02
C
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett